Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEO-JPEG trial in esophagogastric junction adenocarcinoma
jRCTs031230182Phase 3Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jul 2023
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of docetaxel, oxaliplatin, tegafur, fluorouracil and levoleucovorin in gastroesophageal junction adenocarcinoma (3 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Pathological response rate and Overall survival. Started Jul 2023; status: recruiting.
02
Drugs
docetaxeloxaliplatintegafurfluorouracillevoleucovorin
03
Conditions
gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCTs031230182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031230182.